Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease

PURPOSE: This article reviews the efficacy and safety of revefenacin, the first once-daily, long-acting muscarinic antagonist, when delivered via a standard jet nebulizer in patients with chronic obstructive pulmonary disease (COPD). SUMMARY: Revefenacin 175 µg is indicated for the maintenance treat...

Descripción completa

Detalles Bibliográficos
Autor principal: Hvisdas, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083528/
https://www.ncbi.nlm.nih.gov/pubmed/33821890
http://dx.doi.org/10.1093/ajhp/zxab154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083528/
https://www.ncbi.nlm.nih.gov/pubmed/33821890
http://dx.doi.org/10.1093/ajhp/zxab154

Ejemplares similares